Australia Markets closed

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
10.52-0.06 (-0.57%)
At close: 4:00PM EST

10.54 +0.02 (0.19%)
After hours: 6:30PM EST

Full screen
Trade prices are not sourced from all markets
Previous close10.58
Open10.55
Bid10.48 x 2900
Ask10.54 x 800
Day's range10.20 - 10.77
52-week range6.25 - 13.30
Volume10,351,830
Avg. volume9,772,181
Market cap11.488B
Beta (5Y monthly)1.45
PE ratio (TTM)N/A
EPS (TTM)-3.64
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date27 Nov 2017
1y target est12.66
  • 3 Value Stocks That'll Make You Richer in March (and Beyond)
    Motley Fool

    3 Value Stocks That'll Make You Richer in March (and Beyond)

    For more than a decade, growth stocks have left value stocks eating their dust. Historically low lending rates and a record-long bull-market run have wet the appetites of investors looking for game-changing growth stocks. What's more, value stocks have historically outperformed during the early years of an economic recovery.

  • Teva to Present at the J.P. Morgan 2021 Global High Yield and Leveraged Finance Conference
    Business Wire

    Teva to Present at the J.P. Morgan 2021 Global High Yield and Leveraged Finance Conference

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Executive Vice President & CFO Eli Kalif will present at the J.P. Morgan 2021 Global High Yield and Leveraged Finance Conference on Tuesday, March 2, 2021 at 8:30 a.m. Eastern Time.

  • New Study Published in Cephalalgia Identifies Mechanistic Differences Among CGRP Migraine Treatments
    Business Wire

    New Study Published in Cephalalgia Identifies Mechanistic Differences Among CGRP Migraine Treatments

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) highlights results from the in vitro study "Migraine Therapeutics Differentially Modulate the CGRP Pathway," which were published online by Cephalalgia, a monthly journal published on behalf of the International Headache Society. These results will also be featured in a future print issue of the journal. This study demonstrated marked differences in the mechanism of blocking the calcitonin gene-related peptide (CGRP) ligand versus the CGRP receptor.